

**PATIENTTRENDS®: MULTIPLE SCLEROSIS (US) 2012**

***PatientTrends: Multiple Sclerosis** will cover patients' attitudes, perceptions, and behavior regarding their disease, with a focus on the patient's path to diagnosis and their perception of their interaction with their physician. The report will also look at what drives patients' satisfaction with their current multiple sclerosis (MS) treatment, especially with regards to their disease-modifying agent (DMA), and identify which emerging DMA in development may be most likely to initiate a switch discussion from patients.*

*PatientTrends provides indispensable primary market research on patient attitudes and perceptions of both their disease and treatment, with a specific focus on which patient segments in major disease areas offer opportunity for existing or emerging therapies.*

**SAMPLE FRAME AND METHODOLOGY**

This report includes responses from a random sample of approximately 290+ U.S. MS patients

The survey is a self-administered online questionnaire that takes approximately 45 minutes to complete

A qualitative follow up arm includes telephone interviews conducted with a sub-set of 15+ survey respondents

To qualify for participation, patients must meet the following criteria:

- Be between 18 to 80 years of age
- Been diagnosed with MS by a doctor
- Currently using a DMA to treat their MS

**PRODUCT COVERAGE**

Avonex, Betaseron, Copaxone, Gilenya, Rebif, Tysabri, Ampyra

**RELATED 2012 REPORTS**

TreatmentTrends®: Multiple Sclerosis (US)

TreatmentTrends®: Multiple Sclerosis (EU)

ChartTrends®: Multiple Sclerosis (US)

ChartTrends®: Multiple Sclerosis (EU)

Treatment Algorithms: Multiple Sclerosis

LaunchTrends®: Aubagio

LaunchTrends®: Lemtrada

Special Report: Impact of the Anti-JC Virus Antibody Assay

**PRICE**

\$49,500

**PROJECT OBJECTIVES**


- Understand MS patients' path to diagnosis and treatment and their perception of their disease and treatment
- Evaluate whether patient behavior and approach to health differs depending on their current DMA
- Learn how patients' satisfaction with their current MS treatments compares with their expectations for drug treatment
- Analyze what attributes of MS patients' disease and treatment contribute to their brand satisfaction, advocacy, and loyalty
- Evaluate patient unmet need and determine what drug attributes are most likely to encourage a patient to request a switch to an emerging DMA in development

**DELIVERABLES**

- Final report in PowerPoint format
- Complete set of frequency tables, summary statistics, and cross tabulations
- Copies of telephone interviews (as audio files; blinded)
- Proprietary question slide deck and frequency tables
  - Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions


**REPORT DATES**

Date comments/proprietary questions are due	Field date	Publication date
February 21, 2012	March 9, 2012	May 14, 2012




**TABLE OF CONTENTS**

Background, Market News, Methods, and Objectives.....	4
Executive Summary.....	18
Patient Demographics.....	28
Patient Demographics	
Patient Education Level	
Patient Employment	
Patient Insurance and Drug Coverage	
Drug / Medical Benefit Coverage...In Their Own Words	
Specialists Seen in the past Year	
MS Patient Comorbidities	
Initial MS Diagnosis.....	37
Diagnosis: Age and MS Disease Classification	
Circumstances Leading to MS Diagnosis	
MS Diagnosis Experience...In Their Own Words	
Symptoms Prompting Medical Care	
Diagnosing Specialists When Diagnosed at First Visit	
Specialists Referred to for MS Diagnosis	
Specialists Seen Prior to MS Diagnosis	
Diagnosing Specialist and Time to to Diagnosis Among Patients Not Diagnosed at First Visit	
Patient-Recalled Diagnostic Tests	
Time to Initial DMA Prescription	
Delays to DMA Therapy...In Their Own Words	
Disease Education Sources.....	49
Sources for MS Education / Information	
Specific Internet and Advocacy Sources	
Sources of MS Information...In Their Own Words	
Sources for MS Education / Information by DMA Brand	
Current Medical Management.....	54
Current Managing Specialist and Frequency of Clinical Visits	
Patients' Perceptions of Their Influence on MS Management / Treatment	
Patient-Physician Relationship...In Their Own Words	
MS Topics Discussed at Last Clinical Visit	
Current MS Clinical Presentation.....	60
Current MS Disease Classification by DMA Brand	
Current MS Symptoms: Total and by DMA Brand	
Recent MS Exacerbations: Total and by DMA Brand	
Current Impact of MS: Total and by DMA Brand	
Current Impact of MS: Patient versus Physician Perceptions	



**TABLE OF CONTENTS**

Current DMA Therapy.....	69
Use and Awareness of DMAs	
First-Line DMA Decision Process...In Their Own Words	
Patient Demographics by DMA Brand	
Patient Requests for DMAs	
Patient Thoughts on Gilenya...In Their Own Words	
DMA Samples	
Out-of-Pocket Cost for DMAs	
Cost and Insurance Coverage...In Their Own Words	
Sources fro Obtaining DMAs	
Reasons for Not Filling DMA Prescriptions	
DMA Compliance	
Patient Compliance...In Their Own Words	
Reasons for DMA Non-Compliance	
Patient Concern Regarding Specific Potential DMA-Related Side Effects: Total and By DMA Brand	
Experienced Side Effects Associated with Current DMA	
DMA-Related Side Effects...In Their Own Words	
Anti-JC Virus Antibody Assay Testing and Risk Stratification Confidence	
Reasons for DMA Discontinuation	
Former DMA Use by DMA Brand	
Switching Decision Thought Process...In Their Own Words	
DMA Competitive Landscape.....	98
Overall Satisfaction with DMA Brand	
Overall Satisfaction with DMA Brand” Patient versus Physician Perceptions	
DMA Satisfaction...In Their Own Words	
Possible Areas for Current DMA Improvement...In Their Own Words	
Stated Attribute Importance	
Stated Attribute Importance Differences by Current DMA Brand	
DMA Brand Performance Perceptions on Attributes	
DMA Brand Advocacy	
DMA Brand Loyalty	
Pharmaceutical Company-Sponsored Programs.....	111
Participation in Pharmaceutical Company-Sponsored Programs	
Participation in Pharmaceutical Company-Sponsored Programs for Current DMA	
Satisfaction with Pharmaceutical Company-Sponsored Programs	
Company-Sponsored Programs...In Their Own Words	
Statement Agreement.....	117
MS Etiology	
Impact of MS: Total and by DMA Brand	
Medical Management of MS: Total and by DMA Brand	



**TABLE OF CONTENTS**

DMA's in Development.....	123
Desired Improvement for DMA's in Development	
Desired Improvements for DMA's in Development...In Their Own Words	
Unaided Awareness of DMA's in Development	
Aided Awareness of DMA's in Development	
Familiarity of DMA's in Development	
Interest in Switching or Adding DMA's in Development	
Waiting for DMA's in Development...In Their Own Words	
Switching Interest in Alemtuzumab	
Switching / Adding on Interest in BG-12	
Switching / Adding on Interest in Laquinimod	
Switching / Adding on Interest in Teriflunomide	
Symptomatic Management.....	138
Use and Awareness of MS-Related Symptomatic Agents	
Patient Requests for MS-Related Symptomatic Agents	
MS-Related Symptomatic Agents Samples	
Out-of-Pocket Cost for MS-Related Symptomatic Agents	
Sources for Obtaining MS-Related Symptomatic Agents	
Reasons for Not Filling MS-Related Symptomatic Agent Prescriptions	
MS-Related Symptomatic Agent Compliance	
Reasons for MS-Related Symptomatic Agent Non-Compliance	
Reasons for MS-Related Symptomatic Agent Discontinuation	
Overall Satisfaction with MS-Related Symptomatic Brands	
MS-Related Symptomatic Brand Performance Perceptions on Attributes	
MS-Related Symptomatic Brand Advocacy	
MS-Related Symptomatic Brand Loyalty	
Participation in Pharmaceutical Company-Sponsored Programs for Current MS-Related Symptomatic Brands	
Appendix .....	153